Olanzapine: advantages in all-cause discontinuation and efficacy

Quetiapine: advantages in all-cause discontinuation and efficacy for up to 18 wk

Discontinuation rate, efficacy, and tolerability

Patients who had not responded to perphenazine

Olanzapine, quetiapine, risperidone, ziprasidone, clozapine

Risperidone: advantages in tolerability

Ziprasidone: most benign metabolic profile and greater likelihood of weight loss in those who had gained significant weight on other APs

Olanzapine, risperidone, quetiapine, ziprasidone

Results interpreted as switching trials

CATIE: Clinical Antipsychotic Trials of Intervention Effectiveness, large randomized, double-blind, multicenter outpatient trial in the United States evaluating 1 first-generation antipsychotic (perphenazine) and 5 second-generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone, clozapine); duration up to 18 months.

Abbreviations: AP = antipsychotic, BMI = body mass index, CHD = coronary heart disease, PANSS = Positive and Negative Syndrome Scale, PEARL = Program to Evaluate the Antipsychotic Response to Lurasidone study, QOL = quality of life.